Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Rockwell Medical Closes $12.9 Million Registered Direct Common Stock Offering



Rockwell Medical Closes $12.9 Million Registered Direct Common Stock Offering

WIXOM, Mich., March 26, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc.
(Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD) with
innovative products and services for the treatment of iron deficiency,
secondary hyperparathyroidism and hemodialysis, announced today the closing of
the sale of 4,300,000 common shares at $3.00 per share in a registered direct
offering for an aggregate offering amount of approximately $12.9 million. The
net proceeds from the offering, after commissions and other estimated offering
expenses, were approximately $12.0 million. Rockwell Medical plans to use the
net proceeds from the offering for general corporate purposes which may
include research and development expenses, acquisition of intellectual
property relating to complementary drug therapies, funding of clinical trials,
and general administrative expenses.

Chardan Capital Markets, LLC served as the lead placement agent for the
offering and Newbridge Securities, LLC acted as co-placement agent.

The shares of common stock described above were offered pursuant to an
effective shelf registration statement as filed with the Securities and
Exchange Commission. A prospectus supplement relating to the offering was
filed with the Securities and Exchange Commission on March 20, 2013. Copies of
the prospectus supplement and the accompanying prospectus relating to these
securities may be obtained by contacting Rockwell Medical, Inc. c/o Investor
Relations at 30142 S. Wixom Road, Wixom, Michigan 48393. Electronic copies of
the prospectus supplement and accompanying prospectus relating to the offering
may be obtained from the Securities and Exchange Commission website at
http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy shares of common stock of Rockwell Medical and shall not
constitute an offer to sell or a solicitation of an offer to buy any
securities of Rockwell Medical in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction. Any
offer of these securities will be solely by means of a prospectus included in
the registration statement and a prospectus supplement that will be issued in
connection with such offering.

About SFP

SFP is a unique iron compound that is delivered to the hemodialysis patient
via dialysate, replacing the 5-7mg of iron lost during a dialysis treatment.
SFP is introduced into the sodium bicarbonate concentrate that subsequently is
mixed into dialysate. Once in the dialysate, SFP crosses the dialyzer membrane
and enters the bloodstream where it immediately binds to apo-transferrin and
is taken to the bone marrow, mimicking the way dietary iron is handled in the
human body. In completed clinical trials to date, SFP has demonstrated that it
can safely deliver iron and maintain hemoglobin levels, while decreasing ESA
use without any increase in iron stores.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD) with
innovative products and services for the treatment of iron deficiency,
secondary hyperparathyroidism and hemodialysis.

Rockwell's lead drug candidate in late-stage clinical development is for the
treatment of iron deficiency and is called Soluble Ferric Pyrophosphate
(SFP). SFP delivers iron to the bone marrow of dialysis patients in a
non-invasive, physiologic manner via dialysate during their regular dialysis
treatment. In order to prevent or treat anemia, sufficient availability of
iron and erythropoietin must be present in the bone marrow to generate healthy
red blood cells. In completed clinical trials to date, SFP has demonstrated
that it can safely deliver sufficient iron to the bone marrow.

SFP is currently in ongoing Phase 3 clinical studies (CRUISE-1 and CRUISE-2)
to address an estimated $600 million U.S. and $1 billion global market.

Rockwell is also preparing to launch a FDA approved generic drug called
Calcitriol. Calcitriol is active vitamin D injection and indicated for the
treatment of secondary hyperparathyroidism in dialysis patients. Rockwell
intends to enter the vitamin D market in 2013, addressing an estimated $350
million U.S. market.

Rockwell is also an established manufacturer and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis providers and
distributors in the U.S. and abroad. These products are used to maintain human
life, by removing toxins and replacing critical nutrients in the dialysis
patient's bloodstream. Rockwell's has three manufacturing and distribution
facilities in the United States and its operating infrastructure is a
ready-made sales and distribution channel that is able to provide seamless
integration into the commercial market for its drug products, Calcitriol and
SFP upon FDA market approval.

Rockwell's exclusive renal drug therapies support disease management
initiatives to improve the quality of life and care of dialysis patients and
are intended to deliver safe and effective therapy, while decreasing drug
administration costs and improving patient convenience. Rockwell Medical is
developing a pipeline of drug therapies, including extensions of SFP for
indications outside of hemodialysis. Please visit www.rockwellmed.com for more
information. For a demonstration of SFP's unique mechanism of action in
delivering iron via dialysate, please view the animation video at
http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

The Rockwell Medical Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6773

About Chardan Capital Markets, LLC

Chardan is an international investment bank headquartered in New York City,
with offices in Los Angeles, San Francisco and Beijing. Chardan provides a
wide array of banking and advisory services to public and private companies
and institutional investors around the world including Initial Public
Offerings (IPOs), Private Investments in Public Equity (PIPEs), Specified
Purpose Acquisition Companies (SPACs), Merger and Acquisition Advisory
Services, Debt Financing, Private Equity Financing, Venture Capital Financing,
Equity/Derivatives Trading, Non Deal Road Shows, Third Party Marketing of
Hedge Funds, Research and Restructuring.

About Newbridge

Newbridge Financial, Inc. ("NFI") is the parent/holding company for NSC and
NFSG. NSC is a FINRA member broker-dealer that engages in full service
securities brokerage, investment banking and advisory services with a broad
based group of individuals and institutional customer. NFSG is an SEC
Registered Investment Advisor offering a broad spectrum of financial services
including financial, insurance, retirement, estate and tax planning for our
individual and corporate clients. For more information on Newbridge, please
visit our public web-site at www.newbridgefinancial.com or
www.newbridgesecurities.com

Certain statements in this press release constitute "forward-looking
statements" within the meaning of the federal securities laws, including, but
not limited to, Rockwell's intention to launch Calcitriol and SFP following
FDA approval. Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict," "forecast,"
"project," "plan", "intend" or similar expressions, or statements regarding
intent, belief, or current expectations, are forward-looking statements. While
Rockwell Medical believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking statements,
which are based on information available to us on the date of this release.
These forward looking statements are based upon current estimates and
assumptions and are subject to various risks and uncertainties, including
without limitation those set forth in Rockwell Medical's SEC filings. Thus,
actual results could be materially different. Rockwell Medical expressly
disclaims any obligation to update or alter statements whether as a result of
new information, future events or otherwise, except as required by law.

CONTACT: Michael Rice, Investor Relations; (646) 597-6979
         David Connolly, Media Contact; (617) 374-8800

Rockwell Medical Technologies, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement